Sutro Biopharma, Inc.
STRONASDAQHealthcare● Active
$25.95
+$0.54(+2.13%)
Market Cap$251124793
P/E Ratio—
52W High$43.85
52W Low$6.7
Sutro Biopharma, Inc. (STRO) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · STRO · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($0.19B) | ($0.23B) | ($0.11B) | ($0.12B) | ($0.11B) |
| Depreciation & Amort. | $0.01B | $0.01B | $0.01B | $0.01B | $0.00B |
| Stock-Based Comp. | $0.01B | $0.02B | $0.02B | $0.03B | $0.02B |
| Change in Working Capital | ($0.05B) | $0.01B | ($0.03B) | $0.10B | ($0.02B) |
| Net Cash from Operations | ($0.18B) | ($0.19B) | ($0.11B) | $0.00B | ($0.08B) |
| Investing Activities | |||||
| Capital Expenditure | ($0.00B) | ($0.00B) | ($0.00B) | ($0.01B) | ($0.02B) |
| Purchases of Investments | ($0.26B) | ($0.46B) | ($0.46B) | ($0.22B) | ($0.25B) |
| Sales of Investments | $0.31B | $0.68B | $0.46B | $0.19B | $0.17B |
| Net Cash from Investing | $0.05B | $0.22B | ($0.00B) | ($0.04B) | ($0.10B) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00B | $0.00B | $0.00B | $0.00B | ($0.00B) |
| Dividends Paid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | $0.00B | ($0.00B) | ($0.01B) | ($0.01B) | $0.00B |
| Net Cash from Financing | $0.00B | $0.09B | $0.14B | $0.05B | $0.00B |
| Free Cash Flow | |||||
| Free Cash Flow | ($0.18B) | ($0.19B) | ($0.12B) | ($0.00B) | ($0.10B) |
| FCF Margin %(computed) | -174.59% | -313.71% | -75.41% | -6.36% | -156.76% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · B
Explore more Sutro Biopharma, Inc. data
About Sutro Biopharma, Inc. (STRO) Cash Flow Statement
Sutro Biopharma, Inc. generated operating cash flow of ($0.18B) and free cash flow of ($0.18B) for 2025 — a FCF margin of -174.59%. Capital expenditure was ($0.00B).
Frequently asked questions
STRO · 4 questionsSutro Biopharma, Inc. generated free cash flow of ($0.18B) for 2025, up 8.1% year-over-year.
STRO free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10